Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS).

from http://www.alseres.com/

Patents 63show all

  • 36
    A61K - Preparations for medical, dental, or toilet purposes
  • 16
    C07H - Sugars
  • 12
    C07K - Peptides
  • 7
    C07D - Heterocyclic compounds
  • 7
    G21H - Obtaining energy from radioactive sources
  • 4
    A61B - Diagnosis
  • 3
    Y02P - Climate change mitigation technologies in the production or processing of goods
  • 2
    Y02A - Technologies for adaptation to climate change
  • 1
    B41J - Typewriters
  • 1
    C08C - Treatment or chemical modification of rubbers

Clinical Trials 2show all

1Phase 3

SEC Filings show all


195
8-K

55
10-Q

16
10-K

3
D

Contact Information

Newton, MA
United States

SEC Form D Funding Events

DateOfferedSoldType
2009-11-10$1,000,000$1,000,000Equity
2009-08-21$5,000,000$3,900,000Equity
2009-01-23Unknown Unknown Other (Paper Filing)

Key Executives

  • Peter G. Savas
    Executive Officer, Director
  • Mark Pykett
    Executive Officer
  • Kenneth L. Rice, Jr.
    Executive Officer
  • Michael J. Mullen
    Director
  • John T. Preston
    Director
  • William L.s. Guinness
    Director
  • Henry Brem
    Director
  • Gary E. Frashier
    Director
  • Robert Langer
    Director